Revolution Medicines resumes coverage with Outperform rating; price target $288
RVMD•Leerink Partners resumed coverage of Revolution Medicines with an Outperform rating and a $288 price target.
Related News
Atlas Energy Solutions Inc.: Stephens cuts target price to $20 from $22
AESI•
Federal Realty Investment Trust: Wells Fargo cuts target price to $126 from $134
FRT•
Fair Isaac Corporation: Wells Fargo cuts target price to $800 from $950
FICO•
Scotts Miracle-Gro target price cut to $60 from $77
SMG•
Molson Coors Beverage Company: Wells Fargo cuts target price to $38 from $41
TAP•